Replagal
Replagal is a biological therapy with 10 clinical trials. Currently 1 active trials ongoing. Historical success rate of 88.9%.
Success Metrics
Based on 8 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
3
Mid Stage
6
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
88.9%
8 of 9 finished
11.1%
1 ended early
1
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Replagal in Children and Adults With Fabry Disease in India
A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease
A Study of Replagal in Treatment-naïve Adults With Fabry Disease
Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease
Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease
Clinical Trials (10)
A Study of Replagal in Children and Adults With Fabry Disease in India
A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease
A Study of Replagal in Treatment-naïve Adults With Fabry Disease
Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease
Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease
Dosing Study of Replagal in Patients With Fabry Disease
An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease
Alternative Dosing and Regimen of Replagal to Treat Fabry Disease
Replagal Enzyme Replacement Therapy for Adults With Fabry Disease
An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease
All 10 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 10